Minimally Invasive Surgical Instruments Market: as Intuitive Surgical’s instruments and accessories revenue grows faster than its capital equipment revenue, the commercial centre of gravity in robotic-assisted surgery is shifting from the one-time sale of the surgical system itself to the recurring, per-procedure consumable stream that follows every installed system for its operating life, so instrument and accessory manufacturers increasingly capture more durable, forecastable revenue than system placement volume alone would suggest, and the pace of new instrument and accessory introduction is becoming as important a competitive signal as installed base growth.

The global minimally invasive surgical instruments market size was USD 27.84 Billion in 2025 and is expected to register a revenue CAGR of 8.2% during the forecast period. Market revenue growth is driven by factors such as robotic-assisted procedure volume expansion directly increasing per-procedure instrument and accessory consumption, the accelerating pace of new robotic surgical system placements widening the installed base that generates recurring instrument demand, and continued growth in endoluminal and bronchoscopic procedure volume expanding instrument demand beyond traditional laparoscopic categories. The first driving factor is the direct link between robotic-assisted procedure volume growth and instrument and accessory consumption, since every robotic-assisted procedure requires a defined set of single-use or limited-use instruments regardless of the underlying capital equipment already installed. Worldwide da Vinci procedures grew approximately 18% during 2025 to approximately 3,153,000 procedures, and this procedure volume growth translates directly into instrument and accessory demand independent of new system placement activity. The second driving factor is the accelerating pace of new robotic surgical system placements, which expands the installed base generating ongoing instrument and accessory demand for years after each system’s initial sale. More than 1,700 da Vinci surgical systems were placed globally during 2025, of which 870 were da Vinci 5 systems, more than double the 362 da Vinci 5 systems placed in 2024, extending the installed base that drives recurring instrument consumption. The third driving factor is continued growth in endoluminal and bronchoscopic procedure volume, extending instrument demand beyond traditional laparoscopic and robotic-assisted abdominal and pelvic surgery categories. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way instrument and accessory revenue compounds against an installed base of robotic surgical systems as procedure volume on each system grows year over year, letting revenue expand without requiring a new capital equipment sale for every incremental dollar of instrument demand. Once a robotic surgical system is installed at a hospital, every additional procedure performed on that system generates instrument and accessory revenue without requiring any additional capital equipment sale, so instrument and accessory revenue compounds against a growing installed base far more efficiently than capital equipment revenue, which depends on winning a new system placement for each incremental sale. As a result, demand and revenue share are concentrating around instrument and accessory revenue relative to capital equipment revenue within leading manufacturers’ overall business mix, and the forecast tilts toward recurring, per-procedure revenue streams rather than one-time system sales as the primary driver of manufacturer revenue growth. For instance, in the fourth quarter of 2025, Intuitive Surgical, United States, reported instruments and accessories revenue of USD 1.66 Billion, a 17% increase from USD 1.41 Billion in the fourth quarter of 2024, driven by approximately 17% growth in da Vinci procedure volume and approximately 44% growth in Ion endoluminal procedure volume, illustrating how procedure volume growth across multiple platforms compounds instrument and accessory revenue faster than system placement volume alone would generate. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the direct, mechanical link between robotic-assisted procedure volume and instrument and accessory consumption. Every robotic-assisted procedure requires a defined set of single-use or limited-use instruments regardless of when the underlying capital equipment was purchased, so procedure volume growth on an already-installed system base generates instrument revenue growth without requiring any new capital equipment sale, meaning procedure volume and instrument revenue are mechanically linked rather than merely correlated. Worldwide da Vinci procedures grew approximately 18% during 2025 to approximately 3,153,000 procedures, compared with approximately 2,683,000 procedures in 2024, according to Intuitive Surgical’s preliminary fourth quarter and full year 2025 results announced in January 2026. The effect on the market is that instrument and accessory revenue growth increasingly tracks procedure volume on the existing installed base rather than tracking new system placement volume alone. These are some of the key factors driving revenue growth of the market.

The second driver is the accelerating pace of new robotic surgical system placements, specifically the rapid ramp of da Vinci 5 placements relative to the prior generation. A newly placed system does not generate meaningful instrument and accessory revenue immediately, since procedure volume ramps up gradually as surgical teams gain experience, and this is why an accelerating placement pace today signals accelerating instrument and accessory revenue over the following several years rather than an immediate revenue jump, so placement pace acceleration and future instrument revenue growth are directly linked with a lag. Intuitive Surgical placed 1,721 da Vinci surgical systems globally during 2025, of which 870 were da Vinci 5 systems, more than double the 362 da Vinci 5 systems placed during 2024, according to the company’s January 2026 earnings release. The recent record shows the pace. The fourth quarter of 2025 alone included 303 da Vinci 5 system placements, compared with 174 in the fourth quarter of 2024, confirming the acceleration continued through the final quarter of the year. The effect on the market is that the installed base capable of generating recurring instrument and accessory revenue is expanding at an accelerating rate, setting up sustained instrument demand growth over the following several years as these newly placed systems ramp toward full procedure volume. These are some of the key factors driving revenue growth of the market.

“Intuitive Surgical placed 1,721 da Vinci surgical systems globally during 2025, including 870 da Vinci 5 systems, more than double the 362 da Vinci 5 systems placed during 2024, expanding the installed base that generates recurring instrument and accessory revenue for years after each system’s initial placement.”

The third driver is the extension of minimally invasive instrument demand into endoluminal and bronchoscopic procedure categories beyond traditional laparoscopic surgery. Endoluminal bronchoscopic procedures using platforms such as Ion require their own distinct instrument and accessory set separate from traditional laparoscopic or robotic-assisted abdominal surgery instruments, and rapid procedure volume growth in this category represents genuinely incremental instrument demand rather than substitution for existing laparoscopic procedure volume. Ion endoluminal procedure volume grew approximately 44% in the fourth quarter of 2025 compared with the fourth quarter of 2024, according to Intuitive Surgical’s reported results, a substantially faster growth rate than da Vinci procedure volume growth over the same period. The effect on the market is that instrument demand growth is diversifying beyond traditional laparoscopic and robotic-assisted abdominal surgery into a broader range of minimally invasive procedure categories. These are some of the key factors driving revenue growth of the market.

However, the minimally invasive surgical instruments market faces adoption constraints from the high capital expenditure required to acquire a robotic surgical system before any instrument or accessory revenue can be generated, surgeon credentialing and training complexity that delays full procedure volume ramp-up at newly placed systems, and instrument reprocessing and reimbursement policy variation across jurisdictions. Because a robotic surgical system such as da Vinci 5 represents a substantial upfront capital investment before a hospital can begin generating the procedure volume that drives instrument and accessory revenue, smaller community hospitals and ambulatory surgical centres face a genuine capital barrier to entry that concentrates installed base growth, and therefore instrument demand, disproportionately among larger academic and tertiary hospital systems able to absorb the initial capital outlay. Surgeon credentialing and training complexity is a second constraint, because expanding robotic-assisted procedure volume at a newly placed system requires training and credentialing surgical teams before instrument and accessory revenue can be fully realised, and this training requirement adds a meaningful lag between system placement and the point at which a newly installed system reaches its mature procedure volume run rate, which is why an accelerating placement pace today does not translate into an equally immediate acceleration in instrument revenue. Instrument reprocessing and reimbursement policy variation is the third constraint, since different jurisdictions and payers apply varying reimbursement and single-use-versus-reusable-instrument policies, and this variation affects the per-procedure instrument revenue a manufacturer can realise across different markets, meaning instrument revenue growth does not scale uniformly with procedure volume growth across all geographies. These factors substantially limit minimally invasive surgical instruments market growth over the forecast period.

Based on product type, the global minimally invasive surgical instruments market is segmented into handheld MIS instruments, robotic-assisted instruments and accessories, and energy-based surgical devices. Robotic-assisted instruments and accessories hold the largest revenue share, because they command a higher per-procedure revenue rate than conventional handheld instruments, which suits Intuitive Surgical’s reported instruments and accessories revenue growth outpacing overall company revenue growth. Handheld MIS instruments remain established across the broadest range of minimally invasive procedures, including those performed without robotic assistance, and they represent the largest unit volume category even though robotic-assisted instruments generate higher revenue per procedure. Energy-based surgical devices are expected to register rapid revenue growth in the global minimally invasive surgical instruments market over the forecast period, driven by expanding use across both robotic-assisted and conventional laparoscopic procedures, which is why manufacturers continue to expand energy-based device compatibility across multiple platform types.

General and gastrointestinal surgery application is expected to account for a significantly large revenue share in the global minimally invasive surgical instruments market during the forecast period

Based on application, the global minimally invasive surgical instruments market is segmented into general and gastrointestinal surgery, urology and gynaecology, and thoracic and cardiac surgery. General and gastrointestinal surgery holds a significant revenue share, reflecting the broad procedure volume base across abdominal surgical indications that both robotic-assisted and conventional laparoscopic instruments serve. Thoracic and cardiac surgery is expected to register rapid revenue growth in the global minimally invasive surgical instruments market over the forecast period, driven by da Vinci 5’s expanding thoracic procedure indication coverage, which is why this application represents one of the fastest-evolving instrument demand categories within the broader market.

Based on technology, the global minimally invasive surgical instruments market is segmented into robotic-assisted and conventional laparoscopic technology. Conventional laparoscopic technology holds a substantial revenue share, reflecting its continued widespread use across the full range of minimally invasive procedures not requiring robotic assistance. Robotic-assisted technology is expected to register the fastest revenue growth rate in the global minimally invasive surgical instruments market over the forecast period, driven directly by accelerating da Vinci 5 system placements and procedure volume growth, which is why instrument manufacturers continue to prioritise robotic-compatible instrument development.

Based on regional analysis, the minimally invasive surgical instruments market in North America accounted for largest revenue share in 2025. The United States leads because it hosts the largest installed base of robotic surgical systems globally, and because Intuitive Surgical and Stryker both concentrate significant commercial and product development activity in the country. Intuitive Surgical’s worldwide da Vinci installed base reached 11,106 systems as of December 31, 2025, a 12% increase from 9,902 systems a year earlier, with the United States representing the largest single-country share of this installed base. The concentration of the largest robotic surgical system installed base and leading instrument manufacturer commercial activity in the United States also means new instrument and accessory technology is typically launched in the United States first.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, and France represent the three largest national minimally invasive surgical instruments markets within Europe. Da Vinci 5’s July 2025 CE mark approval extended the platform’s availability across the region, and the region’s established minimally invasive surgical infrastructure and CE-marking regulatory pathway under the Medical Device Regulation sustain steady demand. The result is steady rather than rapid growth, shaped more by the region’s already-mature surgical infrastructure than by unmet clinical demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China, Japan, and India represent the three largest national minimally invasive surgical instruments markets within the region. Expanding robotic surgical system installed base growth and rising minimally invasive procedure adoption in China and India are driving new instrument demand from a comparatively lower installed base, leaving more room for growth than in the already-mature North America and Europe markets.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national minimally invasive surgical instruments markets within the region. Private hospital networks in both countries are gradually expanding robotic-assisted surgical capacity, and the indirect effects of Iran-US sanctions and the associated Strait of Hormuz shipping disruption have kept freight and import costs elevated for the specialised surgical instruments that Latin American hospitals depend on through 2026, slowing adoption beyond the region’s main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial minimally invasive surgical instruments markets within the GCC. The UAE is the most established minimally invasive surgical instruments market on the continent given its concentrated private hospital infrastructure, while the wider Gulf states and broader African markets are still building the surgical infrastructure that robotic-assisted procedure adoption depends on.